Autoinjectors Market

Market Overview

The global autoinjectors market size was valued at USD 1209 million in 2021 and is expected to grow at USD 4615.80 million by 2030. The market is expected to grow at a CAGR of 18.23% during the forecast period (2022–2030). Factors such as patient’s preference to choose self injections and demand for biosimilars, significantly drives the autoinjectors market demand by 2030.

An autoinjector is a prefilled syringe with a spring-loaded needle that automatically inserts the needle at the right injection location. The study only analyzes income produced by autoinjector device sales; it does not include money earned by medicine sales. Furthermore, it excludes money earned by fees paid to doctors or healthcare practitioners who recommend various treatments or testing.

Market Dynamics

Patient’s Preference to Choose Self Injections to Boost the Autoinjections Demand

According to a National Center for Biotechnology Information (NCBI) survey done in Europe in 2018, a poll investigated patients' and nurses' preferences for four distinct autoinjectors used for subcutaneous administration of rheumatoid arthritis. This poll evaluated MyClick autoinjector, Humira pen, Molly autoinjector, and SensoReady autoinjector on 11 different criteria.

According to the survey results, customers thought the SensoReady autoinjector was less difficult and simpler. The main reasons were buttonless injection, visual confirmation of dosage administration, and the injection device's simple triangle form, which made it easier to hold. As a result, healthcare professionals and patients were more willing to recommend SensoReady autoinjectors to rheumatoid arthritis patients.

Initially, autoinjectors were utilized in emergency and military applications to allow patients with severe allergies to self-inject epinephrine. Their scope has expanded, and now these can be used for arthritis and asthma. Furthermore, as new treatment areas emerge and allow patients to self-administer, the number of new patient groups in need of autoinjectors grows.

Furthermore, many manufacturers collaborate with human factor specialists to design autoinjectors, such as the type of device, shape, and form desired by patients. Extra features, such as connection capabilities, are already in high demand in patient-acceptable devices. These considerations by manufacturers promote patients' preference for autoinjectors and improve consumers' choice of medicine delivery method.

General Injections and Oral Tablets Options to Hamper the Autoinjectors Market Growth

Since the patient's care provider focuses on alternate administration methods such as oral, nasal, and topical routes, conventional injectables are uncomfortable and intrusive. The oral route is the most popular and favored method of medication administration since it is simple to use, cost-effective, and safe.

Most chronic illnesses are managed with daily oral medication administration, which is convenient. Furthermore, adherence to oral drugs is generally greater than 50% among patients receiving therapy. These other solutions are less expensive, and patients are more aware of them than autoinjectors. As a result, patients are more inclined to select these solutions when choosing a treatment choice. Furthermore, there is a growing desire for needle-free products.

Patent Expiry of Biologics to Increase Biosimilar Demands Providing Profitable Opportunities

Demand for biosimilars has expanded dramatically due to cheaper pricing with comparable effectiveness and quality to branded medications. Many biologics patents may expire soon, increasing the need for biosimilars. These biosimilars provide a low-cost alternative, putting pricing pressure on the autoinjectors market and increasing competition. Biosimilars' effectiveness and therapeutic results are recognized by specialty doctors and nurse practitioners. Payers and patients are looking to biosimilars as a way to decrease costs and provide better treatment options.

Furthermore, governments and insurance companies favor biosimilars and generics. Owing to their low cost, biosimilars are a tempting alternative to branded biologics, and cost reductions may compel insurance companies to convert to biosimilars.

Eli Lilly introduced a generic version of its trademark insulin at half the price in March 2019. Furthermore, in the United States, CVS Caremark, a CVS Health prescription benefit management company, has replaced branded injectable medications such as EpiPen (by Mylan) and Copaxone (by Teva) with the generic version of Glatiramer Acetate (Autoinjector) by Mylan. As many injectables used to treat chronic illnesses are biologics, the expiration of patents and rising support from governments and insurance providers present a chance for expansion.

Regional Analysis

Significant Growth in North America and Europe

The three main North American countries are the United States, Canada, and Mexico. The United States is a mature market and the major revenue contributor in North America. The presence of major important companies in the area, such as Becton, Dickinson and Company, Mylan, and Novartis, contributes significantly to the autoinjectors market's growth.

Furthermore, an increase in the prevalence of chronic diseases such as anaphylaxis, diabetes, anemia, and rheumatoid arthritis; an increase in demand for autoinjectors; the presence of advanced healthcare facilities; and an increase in the number of R&D activities to develop innovative devices all contribute to the growth of the market in North America. According to the American College of Rheumatology, almost 54.4 million new patients were diagnosed with rheumatoid arthritis in 2018. Arthritis is a major global problem and the main cause of disability in the United States.

Europe's major countries include Germany, Spain, Italy, the United Kingdom, France, and the rest of Europe. In 2019, Europe held the second-largest share of the autoinjectors industry. The rising frequency of chronic illnesses, as well as increased private-sector investment in research & development, are likely to fuel the expansion of the market.

Furthermore, the rise of biologics and biosimilars is having a significant impact on the development of pipelines and strategies for product-market entrance in the European market. The robust pipeline of new pharmaceuticals set to be released will fuel autoinjector growth over the projected period since these drugs will be utilized in conjunction with the autoinjector device.

Segmental Analysis

The autoinjectors market is divided into two types: disposable autoinjectors and reusable autoinjectors. Since key companies are focused on developing autoinjector devices, the disposable autoinjectors segment was the largest revenue contributor in 2019 and is expected to increase at a high rate. Furthermore, the rising occurrence of anaphylaxis is likely to increase demand for autoinjectors, propelling the market forward even further.

The autoinjectors market is divided into several applications, including rheumatoid arthritis, anaphylaxis, multiple sclerosis, and others. Because of the increased incidence of autoimmune disorders and the number of patients sticking to a treatment regimen, the anaphylaxis sector is expected to dominate the global market. The anaphylaxis segment is expected to create the most revenue in the global market during the forecast period.

Due to rising patient demand for autoinjectors and an increase in the occurrence of anaphylaxis, the home care settings sector is likely to dominate the global market. During the forecast period, the home care settings segment is expected to create considerable global autoinjectors market revenue.

Impact of covid-19

The COVID-19 pandemic has caused a global healthcare crisis, resulting in a change in healthcare delivery in most areas. Most unrelated surgeries were postponed in the first half of 2020 to slow the spread of the virus and reduce the strain on healthcare infrastructure. According to Indiana University researchers, healthcare visits declined by approximately 40% in the first six weeks of the pandemic in the U.S, from early March to mid-April.

Following the relaxation of constraints, there has been a general decrease in people postponing seeking care and treatment in healthcare facilities. Furthermore, the slowdown in clinical trial enrollment has pushed back the launch of novel treatments. These considerations may have had a detrimental influence on the autoinjector industry, particularly with its usage in healthcare facilities beginning in early 2020.

However, the overall effect on the autoinjectors market is considered positive, especially during the forecast period, due to several factors. In the biologics space, there has been a shift toward higher delivery volumes and less frequent dosing, which can be achieved through suitably customized autoinjectors.

The COVID-19 pandemic has accelerated the trend of self-injection, allowing patients to be more involved and in charge of their treatment. The trend boosted newer technology in the autoinjector market for improved regulation of injection speed, injection site discomfort, and treatment of anxiety.

Recent Developments

• November 2017 – Amgen launched ENBREL Mini Single-Dose Prefilled Cartridge along with AutoTocuhReusableAutoinjector. ENBREL is used to treat patients with arthritis and moderate-to-severe plaque psoriasis (PsO). The Mini ENBREL with AutoTouch is available in the U.S.
• December 2021 – Antares Pharma announced the divestiture of Otrexup injection for treating rheumatoid arthritis to a subsidiary of AssertioHldings, Inc, a pharmaceutical company.
• August 2018 – Antares Pharma announced an agreement with Pfizer to develop a combination drug-device. This utilizes Antares QuickShot with an undisclosed Pfizer drug, and Antares Pharma receives royalties on net sales on the combination product.
• August 2018 – Antares Pharma received FDA approval for Teva’s epinephrine auto-injector drug-device combination product, which is used to treat severe allergic reactions,